M. Derome-Tremblay, The Story of Dexfenfluramine and Its History over the Past 30 Years. S. Nicolaidis and R. Essner, Marketing in the United States: Labeling and Major Marketing Options. G. Bray, New Trends in the Management of Obesity in the U.S. Pharmacological Profile: R. Wurtman, Brain Neurotransmitters. S. Garattini, Neurochemical Mode of Action of Drugs Which Modify Feeding via 5HT System. J. Blundell, Effects on Eating Patternsand Motivation in Humans Methods for Assessing Neurochemical Changes and their Effect: M. Kalia, The Signifcance of DF Induced Neurochemical Changes, 1976&150#1995. J. OCallaghan, Glial Reaction as an Indicator of Neurotoxicity. R. Moore, The Long-Term DF Study. S. Lorens, DF Effects on Behaviour. B. Campbell, Pharmacokinetic Consideration in Assessing Neurochemical Changes. Therapeutic Efficacy: G. Cooper and R. Sandage, Overview of the Clinical Data. B.Guy-Grand, The INDEX Study: New Data. R. Noble, An 18-Month Study in Overweight American Patients. G. Faich, PPH/Key Discussion Points. N. Laudignon and M. Rebuffe-Scrive, Overview of the Safety Data. Round Table Discussion: V. Itallie, Benefit/Risk Ration of the Treatment of Obesity.